clinical trials

Otsuka’s $886M-plus drug just flopped in its first crucial PhIII trial for frontline AML
Otsuka’s $886M-plus drug just flopped in its first crucial PhIII trial for frontline AML
Endpoints
Otsuka
SGI-110
clinical trials
AML
Flag link:
Why the Latest Alzheimer’s Drug Study Has So Many People Confused
Why the Latest Alzheimer’s Drug Study Has So Many People Confused
Fortune
Biogen
Eisai
BAN2401
clinical trials
Alzheimer's disease
Flag link:
Constrained peptides’ time to shine?
Constrained peptides’ time to shine?
Nature
drug development
clinical trials
R&D
contstrained peptides
Flag link:
RedHill’s RHB-104 hits primary endpoint in Crohn’s phase 3
RedHill’s RHB-104 hits primary endpoint in Crohn’s phase 3
Fierce Biotech
Redhill Biopharma
clinical trials
Crohn's Disease
RHB-104
Flag link:
Sienna slumps as acne asset flunks phase 3 trials
Sienna slumps as acne asset flunks phase 3 trials
Fierce Biotech
Sienna Biopharmaceuticals
clinical trials
acne
SNA-001
Flag link:
Viagra Clinical Trial of Pregnant Women Ends After 11 Babies Die as a Result of Lung Problems
Viagra Clinical Trial of Pregnant Women Ends After 11 Babies Die as a Result of Lung Problems
Xtalks
clinical trials
Viagra
pregnancy
drug safety
generics
Flag link:
Eisai, Biogen outline a 30% and 47% advantage for their Alzheimer’s drug BAN2401 — but critics drag stock down
Eisai, Biogen outline a 30% and 47% advantage for their Alzheimer’s drug BAN2401 — but critics drag stock down
Endpoints
Biogen
Eisai
Alzheimer's disease
BAN2401
clinical trials
Flag link:
Merck claims a needed win for Keytruda with interim OS data in head and neck cancer
Merck claims a needed win for Keytruda with interim OS data in head and neck cancer
Endpoints
Merck
Keytruda
clinical trials
squamous cell carcinoma of the head and neck
Flag link:
Can Celgene's latest Revlimid win reverse the company's bad-news streak?
Can Celgene's latest Revlimid win reverse the company's bad-news streak?
Fierce Pharma
Celgene
Revlimid
clinical trials
Roche
Rituxan
non-Hodgkin lymphoma
Flag link:
Immunicum AB Announces FDA Approval to Expand Ph Ib/II trial of Cancer Drug
Immunicum AB Announces FDA Approval to Expand Ph Ib/II trial of Cancer Drug
CP Wire
Immunicum
clinical trials
ilixadencel
head and neck cancer
non-small cell lung cancer
gastric cancer
Flag link:
Patient death prompts FDA hold on Mersana’s lead cancer ADC
Patient death prompts FDA hold on Mersana’s lead cancer ADC
Fierce Biotech
Mersana
XMT-1522
antibody-drug conjugate
patient deaths
clinical trials
Flag link:
Doctors could prescribe drugs more accurately — if they could get the data
Doctors could prescribe drugs more accurately — if they could get the data
Stat
physicians
clinical trials
clinical trial data
Flag link:
Are We on the Cusp of a Big Alzheimer's Disease Breakthrough?
Are We on the Cusp of a Big Alzheimer's Disease Breakthrough?
Motley Fool
Alzheimer's disease
clinical trials
Biogen
drug development
BAN2401
Flag link:
Celgene tweaks trial of myeloma CAR-T bb2121, raising dose
Celgene tweaks trial of myeloma CAR-T bb2121, raising dose
Fierce Biotech
Celgene
clinical trials
bb2121
Bluebird Bio
Multiple Myeloma
CAR-T
Flag link:
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug
Xconomy
Dravet syndrome
clinical trials
Zogenix
ZX008
FenPhen
GW Pharma
Epidiolex
Flag link:
Seattle Genetics Doses First Patient In Ph II Trial of Antibody-drug Conjugate in Multiple Solid Tumors
Seattle Genetics Doses First Patient In Ph II Trial of Antibody-drug Conjugate in Multiple Solid Tumors
CP Wire
Seattle Genetics
colorectal cancer
non-small cell lung cancer
pancreatic cancer
head and neck cancer
cervical cancer
tisotumab vedotin
Genmab
clinical trials
Flag link:
Johnson & Johnson, looking for its Tremfya niche, starts up new trial program in Crohn's
Johnson & Johnson, looking for its Tremfya niche, starts up new trial program in Crohn's
Fierce Pharma
JNJ
Tremfya
MorphoSys
Janssen
Crohn's Disease
clinical trials
Flag link:
AbbVie's stock falls after lymphoma treatment trial data disappoints
AbbVie's stock falls after lymphoma treatment trial data disappoints
Marketwatch
AbbVie
ibrutinib
clinical trials
lymphoma
Flag link:
Seattle Genetics Announces Results of Two Ph II Trials of Tucatinib in HER2- Positive Metastatic Breast Cancer
Seattle Genetics Announces Results of Two Ph II Trials of Tucatinib in HER2- Positive Metastatic Breast Cancer
CP Wire
Seattle Genetics
tucatinib
orphan drugs
clinical trials
HER2-positive metastatic breast cancer
breast cancer
Flag link:
Aquinox discards lead drug, chops half of its staff in wake of PhIII disaster
Aquinox discards lead drug, chops half of its staff in wake of PhIII disaster
Endpoints
layoffs
Aquinox
rosiptor
clinical trials
Flag link:

Pages